Fierce news: There's an app for that now

When running into readers at industry conferences or the occasional chance encounter, I ask two questions:

1) How can we improve and serve your business news needs better? 
2) What's your preferred way of reading Fierce--e-mail newsletter or on the web?

In years past, readers preferred the e-mail newsletter (FierceBiotech and FiercePharma now enjoy more than 110,000 unique daily e-mail readers) followed by our websites (250,000+ unique monthly visitors). And while e-mail and web continue to be the most popular way to interact with our content, we're carefully studying the evolving news consumption habits of our readers so we continue meeting their needs. An example includes the real-time Twitter updates we began early last year. @FierceBiotech, @FiercePharma, and @JohnCFierce now have a combined 5,500 followers. 

Today we're expanding our reach even further with launch of the FierceMarkets Mobile App--available immediately for iPhone, Blackberry, Android, and Windows Mobile devices. These apps were designed with our smartphone-toting readers in mind, providing a portable way to catch up on news that's important across all of our industry verticals. We also built in our jobs board, sharing for Facebook and Twitter, and a tool for saving articles to read later. 

Our mission is to be the first place you turn for industry news and analysis. If you conduct a significant amount of business on your phone, download our mobile app and tell us how we're doing.  

- Arsalan Arif, Publisher (e-mail me | follow me on Twitter)

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.